Industry
Biotechnology
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.
Loading...
Open
1.04
Mkt cap
44M
Volume
411K
High
1.08
P/E Ratio
-0.64
52-wk high
1.76
Low
1.01
Div yield
N/A
52-wk low
0.63
Portfolio Pulse from
November 19, 2024 | 12:15 pm
Portfolio Pulse from Vaishali Prayag
September 19, 2024 | 4:07 pm
Portfolio Pulse from Benzinga Newsdesk
September 19, 2024 | 2:29 pm
Portfolio Pulse from Benzinga Newsdesk
September 19, 2024 | 11:12 am
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 11:17 am
Portfolio Pulse from Benzinga Newsdesk
May 22, 2024 | 11:07 am
Portfolio Pulse from Benzinga Newsdesk
April 05, 2024 | 10:38 am
Portfolio Pulse from Benzinga Newsdesk
April 05, 2024 | 10:32 am
Portfolio Pulse from Avi Kapoor
April 04, 2024 | 6:39 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.